Details for Patent: 10,208,089
✉ Email this page to a colleague
Which drugs does patent 10,208,089 protect, and when does it expire?
Patent 10,208,089 protects ZILBRYSQ and is included in one NDA.
This patent has seventy-seven patent family members in twenty-five countries.
Summary for Patent: 10,208,089
| Title: | Modulation of complement activity |
| Abstract: | The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics. |
| Inventor(s): | Hoarty Michelle Denise, Dhamnaskar Ketki Ashok, Elbaum Daniel, Josephson Kristopher, Larson Kelley Cronin, Ma Zhong, Nims Nathan Ezekiel, Ricardo Alonso, Seyb Kathleen, Tang Guo-Qing, Treco Douglas A., Wang Zhaolin, Ye Ping, Zheng Hong, Perlmutter Sarah Jacqueline, Hammer Robert Paul |
| Assignee: | Ra Pharmaceuticals, Inc. |
| Application Number: | US16128561 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,208,089
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Try a Trial | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Try a Trial | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-003 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,208,089
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015274482 | ⤷ Try a Trial | |||
| Australia | 2019200828 | ⤷ Try a Trial | |||
| Australia | 2021204313 | ⤷ Try a Trial | |||
| Brazil | 112016029076 | ⤷ Try a Trial | |||
| Brazil | 122023024819 | ⤷ Try a Trial | |||
| Canada | 2949985 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
